Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 22 May 24 424B3 Prospectus supplement
- 8 Apr 24 EFFECT Notice of effectiveness
- 5 Apr 24 POS AM Prospectus update (post-effective amendment)
- 1 Apr 24 POS AM Prospectus update (post-effective amendment)
- 2 Sep 22 424B4 Prospectus supplement with pricing info
- 30 Aug 22 EFFECT Notice of effectiveness
- 18 Aug 22 S-1/A IPO registration (amended)
-
4 Aug 22 S-1/A IPO registration (amended)
- 2 Aug 22 S-1/A IPO registration (amended)
- 27 Jul 22 S-1/A IPO registration (amended)
- 16 Jun 22 S-1/A IPO registration (amended)
- 25 May 22 FWP Free writing prospectus
- 25 May 22 S-1/A IPO registration (amended)
- 25 Apr 22 S-1 IPO registration
BIAF similar filings
Filing view
External links
EXHIBIT 16.1
August 4, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read bioAffinity Technologies, Inc.’s statements included in its Form S-1 dated August 4, 2022, and are in agreement with the statements contained in the Management’s Discussion and Analysis of Financial Conditions and Results of Operations section titled “Change in Auditors” in the first four paragraphs of that section therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP